OncoMatch/Clinical Trials/NCT06561685
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Is NCT06561685 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for metastatic solid tumor.
Treatment: LY4050784 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed · Paclitaxel · Nab paclitaxel — The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: SMARCA4 any alteration
Presence of any alteration in SMARCA4 (BRG1) [Phase 1a dose escalation]
Required: SMARCA4 known or likely loss of function alteration
known or likely loss of function alteration in SMARCA4 (BRG1) [Phase 1b expansion Parts A, B, C]
Required: SMARCA4 loss of protein expression
loss of protein expression [Phase 1b expansion Parts A, B, C]
Excluded: SMARCA2 known or likely loss of function alteration
Participants with known or likely loss of function alteration of SMARCA2 (BRM) or malignancy with known association with SMARCA2 (BRM) alterations
Disease stage
Required: Stage III, IV
locally advanced and not suitable for definitive locoregional therapy, or metastatic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — advanced or metastatic
Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease
Must have received: any systemic therapy — advanced or metastatic
Participants must have received at least one line of therapy for advanced or metastatic disease [Phase 1b expansion (Part A)]
Cannot have received: SMARCA2 inhibitor
Exception: prior exposure may be permitted for dose escalation
Prior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)
Lab requirements
Cardiac function
No significant cardiovascular disease; no history of increased risk of prolonged QT or significant arrhythmia
Participants with history of increased risk of prolonged QT or significant arrythmia; Significant cardiovascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA · Santa Monica, California
- University of Colorado Health Hospital · Aurora, Colorado
- Sarah Cannon Research Institute at HealthOne · Denver, Colorado
- Florida Cancer Specialists ORLANDO/DDU · Lake Mary, Florida
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify